KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Return on Sales (2016 - 2025)

Vertex Pharmaceuticals has reported Return on Sales over the past 17 years, most recently at 0.37% for Q4 2025.

  • Quarterly results put Return on Sales at 0.37% for Q4 2025, up 6.0% from a year ago — trailing twelve months through Dec 2025 was 0.33% (up 38.0% YoY), and the annual figure for FY2025 was 0.33%, up 38.0%.
  • Return on Sales for Q4 2025 was 0.37% at Vertex Pharmaceuticals, up from 0.35% in the prior quarter.
  • Over the last five years, Return on Sales for VRTX hit a ceiling of 0.43% in Q3 2021 and a floor of 1.36% in Q2 2024.
  • Median Return on Sales over the past 5 years was 0.37% (2022), compared with a mean of 0.26%.
  • Biggest five-year swings in Return on Sales: crashed -173bps in 2024 and later soared 171bps in 2025.
  • Vertex Pharmaceuticals' Return on Sales stood at 0.37% in 2021, then dropped by -4bps to 0.36% in 2022, then increased by 8bps to 0.38% in 2023, then dropped by -19bps to 0.31% in 2024, then grew by 19bps to 0.37% in 2025.
  • The last three reported values for Return on Sales were 0.37% (Q4 2025), 0.35% (Q3 2025), and 0.35% (Q2 2025) per Business Quant data.